image A “groundbreaking” injunction has been sought by US authorities against Indian pharmaceutical giant Ranbaxy.

Officials say that the maker of the first generic version of a cholesterol-lowering drug has failed to meet US safety guidelines.

Citing manufacturing and data integrity shortcomings, the Justice Department said US food safety authorities want to block the company from doing business here because its actions made “many of Ranbaxy’s drugs adulterated, potentially un…